A single-dose pharmacokinetic (PK) study of lasofoxifene in healthy volunteers and subjects with mild or moderate hepatic impairment

被引：0
|
作者：
Bramson, C
Ouellet, D
Roman, D
Randinitis, E
Gardner, MJ
机构：
[1] Pfizer Inc, Ann Arbor, MI USA
[2] Pfizer Inc, Groton, CT 06340 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2004年 / 44卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
19
引用
收藏
页码：1189 / 1189
页数：1
相关论文
共 50 条
  • [1] A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment
    Bramson, C
    Ouellet, D
    Roman, D
    Randinitis, E
    Gardner, MJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01): : 29 - 36
  • [2] A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment
    Marbury, T.
    Stonerock, R.
    Acharya, M.
    Gonzalez, M.
    Jiao, J.
    Breeding, J.
    Haqq, C.
    Molina, A.
    Tran, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S501 - S501
  • [3] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
  • [4] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Akifumi Kurata
    Takafumi Yoshida
    Megumi Inoue
    Tomoko Ishizuka
    Takafumi Nakatsu
    Takako Shimizu
    Manabu Kato
    Yasuhiro Nishikawa
    Hitoshi Ishizuka
    [J]. Advances in Therapy, 2020, 37 : 253 - 264
  • [5] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Kurata, Akifumi
    Yoshida, Takafumi
    Inoue, Megumi
    Ishizuka, Tomoko
    Nakatsu, Takafumi
    Shimizu, Takako
    Kato, Manabu
    Nishikawa, Yasuhiro
    Ishizuka, Hitoshi
    [J]. ADVANCES IN THERAPY, 2020, 37 (01) : 253 - 264
  • [6] Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
    Vidya Perera
    Grigor Abelian
    Danshi Li
    Zhaoqing Wang
    Liping Zhang
    Susan Lubin
    Wei Chen
    Akintunde Bello
    Bindu Murthy
    [J]. Clinical Pharmacokinetics, 2022, 61 : 857 - 867
  • [7] Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
    Perera, Vidya
    Abelian, Grigor
    Li, Danshi
    Wang, Zhaoqing
    Zhang, Liping
    Lubin, Susan
    Chen, Wei
    Bello, Akintunde
    Murthy, Bindu
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (06) : 857 - 867
  • [8] An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment
    Nakamaru, Yoshinobu
    Kakubari, Masae
    Yoshida, Kaori
    Akimoto, Makoto
    Kondo, Kazuoki
    [J]. CLINICAL THERAPEUTICS, 2020, 42 (09) : 1699 - 1714
  • [9] Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects
    Patel, Chirag
    Castaneda, Lorna
    Frevert, Uli
    Li, Li
    Kornhauser, David M.
    Boulton, David W.
    [J]. DIABETES, 2008, 57 : A160 - A160
  • [10] Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment
    Barbhaiya, RH
    Shukla, UA
    Greene, DS
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 49 (03) : 221 - 228
12345